Research programme: CXCR4-targeted radiopharmaceuticals - Alpha-9 Oncology
Latest Information Update: 10 Jan 2024
At a glance
- Originator Alpha-9 Theranostics
- Developer Alpha-9 Oncology
- Class Antineoplastics; Peptides; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Jan 2024 Alpha-9 Theranostics is now called Alpha-9 Oncology
- 09 Feb 2023 Preclinical trials in Solid tumours in USA (unspecified route) before February 2023 (Alpha-9 Theranostics pipeline, February 2023)
- 16 Jun 2020 Alpha-9 Theranostics in-licenses an unique platform technology from the University of British Columbia and BC Cancer